Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-020-00920-z
Abstract: Protease inhibitors such as darunavir are an important therapeutic option in the anti-human immunodeficiency virus arsenal. Current dosage guidelines recommend using cobicistat- or ritonavir-boosted darunavir 800 mg every 24 h (q24h) in protease inhibitor-naïve patients,… read more here.
Keywords: pharmacokinetic modeling; darunavir; population pharmacokinetic; using population ... See more keywords
Pharmacokinetics of initial full and subsequent reduced doses of S-1 in patients with locally advanced head and neck cancer—effect of renal insufficiency
Sign Up to like & getrecommendations! Published in 2017 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyx006
Abstract: Background S-1 is a combination of tegafur [metabolized to 5-fluorouracil (5-FU)] with the modulators gimeracil (5-chloro-2,4-dihydroxypyridine) and oteracil potassium. 5-Chloro-2,4-dihydroxypyridine maintains plasma 5-FU concentrations by inhibiting dihydropyrimidine dehydrogenase, a pyrimidine catabolism enzyme that degrades 5-FU.… read more here.
Keywords: pharmacokinetics initial; renal insufficiency; chloro dihydroxypyridine; insufficiency ... See more keywords
Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection
Sign Up to like & getrecommendations! Published in 2018 at "Rheumatology"
DOI: 10.1093/rheumatology/kex446
Abstract: Objective To investigate maintenance of rituximab (RTX) in RA patients re-treated with reduced doses compared with standard dose in a real life setting. Methods The Autoimmunity and Rituximab (AIR) registry is a nationwide prospective observational… read more here.
Keywords: maintenance; air registry; standard dose; rtx ... See more keywords
Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Internal Medicine"
DOI: 10.1111/joim.12683
Abstract: Comparative data of non‐vitamin K antagonist oral anticoagulants (NOAC) are lacking in patients with atrial fibrillation (AF). read more here.
Keywords: atrial fibrillation; standard reduced; rivaroxaban apixaban; doses dabigatran ... See more keywords
SAT0184 Therapeutic drug monitoring on rheumatoid arthritis patients with reduced doses of intravenous tocilizumab
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.4518
Abstract: Background Tocilizumab (TCZ) is an effective treatment for rheumatoid arthritis (RA). Literature suggests there is great variability in intravenous (iv) TCZ serum concentrations among individuals. Moreover, optimal drug dosage does not seem to be clear… read more here.
Keywords: serum concentrations; tcz; drug; rheumatoid arthritis ... See more keywords
Evaluation of indications for reduced-dose non-vitamin K antagonist oral anticoagulants in hospitalised patients with atrial fibrillation.
Sign Up to like & getrecommendations! Published in 2018 at "Kardiologia polska"
DOI: 10.5603/kp.a2018.0056
Abstract: BACKGROUND Prevention of thromboembolic complications is a priority in patients with atrial fibrillation (AF). The use of non-vitamin K antagonist oral anticoagulants (NOACs) is more common and some patients have indications for a reduced dose.… read more here.
Keywords: atrial fibrillation; receiving reduced; reduced dose; patients receiving ... See more keywords